# MOTS-c peptide References and Citations

> MOTS-c peptide references and citations: the peer-reviewed studies, reviews, and FDA regulatory sources underlying this depth-graded research digest, with DOIs and PubMed URLs.

The peer-reviewed literature and FDA regulatory sources behind every quantitative claim on this site, with DOIs and PubMed identifiers for verification.

## How these sources are used

Every quantitative claim in this digest maps to a numbered source in this list of [MOTS-c references and citations](/references). The peptide science is drawn from peer-reviewed journals indexed on PubMed; the regulatory facts on the [MOTS-c legal status and 503A access](/legal-status) page are drawn exclusively from FDA primary sources. Where the evidence is observational or single-lab, the body copy says so rather than overstating it. The same sources answer the questions in the [MOTS-c FAQ](/faq).

## References

[1] Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. https://pubmed.ncbi.nlm.nih.gov/25738459/
[2] Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. https://pubmed.ncbi.nlm.nih.gov/33473109/
[3] Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018;28(3):516-524.e7. https://pubmed.ncbi.nlm.nih.gov/29983246/
[4] Wan W, Zhang L, Lin Y, Rao X, Wang X, Hua F, Ying J. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. J Transl Med. 2023;21(1):36. https://pubmed.ncbi.nlm.nih.gov/36670507/
[5] Du C, Zhang C, Wu W, Liang Y, Wang A, Wu S, Zhao Y, Hou L, Ning Q, Luo X. Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance. Pediatr Diabetes. 2018;19(5):1058-1064. https://pubmed.ncbi.nlm.nih.gov/29691953/
[6] Luo YH, Xie L, Li JY, Xie Y, Li MQ, Zhou L. Serum MOTS-C Levels are Decreased in Obese Children and Associated with Vascular Endothelial Function. Diabetes Metab Syndr Obes. 2023;16:1125-1133. https://pubmed.ncbi.nlm.nih.gov/37077579/
[7] Lu H, Wei M, Zhai Y, Li Q, Ye Z, Wang L, Luo W, Chen J, Lu Z. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. J Mol Med (Berl). 2019;97(4):473-485. https://pubmed.ncbi.nlm.nih.gov/30725119/
[8] Kim SJ, Xiao J, Wan J, Cohen P, Yen K. Mitochondrially derived peptides as novel regulators of metabolism. J Physiol. 2017;595(21):6613-6621. https://pubmed.ncbi.nlm.nih.gov/28574175/
[9] Kim SJ, Miller B, Kumagai H, Silverstein AR, Flores M, Yen K. Mitochondrial-derived peptides in aging and age-related diseases. GeroScience. 2020;43(3):1113-1121. https://pubmed.ncbi.nlm.nih.gov/32910336/
[10] Kumagai H, Kim SJ, Miller B, et al. MOTS-c modulates skeletal muscle function by directly binding and activating CK2. iScience. 2024;27(11):111212. https://pubmed.ncbi.nlm.nih.gov/39559755/
[11] Bolignano D, Greco M, Presta P, Duni A, et al. The Mitochondrial-Derived Peptide MOTS-c May Refine Mortality and Cardiovascular Risk Prediction in Chronic Hemodialysis Patients: A Multicenter Cohort Study. Blood Purif. 2024;53(9-10):779-789. https://pubmed.ncbi.nlm.nih.gov/39111290/
[12] Pham T, Taberner A, Hickey A, Han JC. Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart. Front Physiol. 2025;16:1602271. https://pubmed.ncbi.nlm.nih.gov/40661667/
[13] Parseh S, Shakerian S, Tabandeh MR, Habibi A. An 8-week study on the effects of high and moderate-intensity interval exercises on mitochondrial MOTS-C changes and their relation to metabolic markers in male diabetic sand rats. Diabetes Res Clin Pract. 2024;211:111656. https://pubmed.ncbi.nlm.nih.gov/38636847/
[14] Shen Z, Lu P, Jin W, et al. MOTS-c Promotes Glycolysis via AMPK-HIF-1alpha-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury. Am J Respir Cell Mol Biol. 2025;72(6):615-628. https://pubmed.ncbi.nlm.nih.gov/40035775/
[15] Li K, Yang T, Chen F, et al. MOTS-c attenuates mitochondrial dysfunction, induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism. Free Radic Biol Med. 2025;238:1-14. https://pubmed.ncbi.nlm.nih.gov/41043625/
[16] U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA.gov (verified 2026-05-29). Establishes the 503A/503B compounding framework, the bulk-substance eligibility rules, the public nomination process, and the role of the Pharmacy Compounding Advisory Committee (PCAC). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
[17] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. FDA.gov (verified 2026-05-29). The published list of nominated bulk drug substances FDA identified as raising significant safety risks for 503A compounding. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
[18] U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar (verified 2026-05-29). Lists BPC-157, KPV, TB-500, and MOTS-c as bulk drug substances being considered for inclusion on the 503A Bulks List; a scheduled discussion, not a decision. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

---

A depth-gauged reading of the MOTS-c mitochondrial-peptide record — the human signal logged near the surface, the preclinical findings in the mid-water, and the honest gaps left visible in the abyss, with no clinic behind the gauge and nothing here stocked, priced, or sold.